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Purpose: To determine the anti-inflammatory and anti-oxidant effects of epigallocatechin gallate (EGCG), the major
polyphenol component of green tea, in human corneal epithelial cells (HCEpiC).
Methods: HCEpiC were challenged with interleukin-1β (IL-1β) for 18 h or hyperosmolarity (440 mOsm) for 24 h.
Luminex technology was used to determine the effects of EGCG (0.3 – 30 µM) on IL-1β- or hyperosmolar-induced
cytokine release into the medium. Cell metabolic activity was measured using the alamarBlue assay. Effects of EGCG on
mitogen-activated protein kinase (MAPK) phosphorylation were determined by cell-based enzyme-linked immunosorbent
assay (ELISA) and western blotting. Effects of EGCG on nuclear factor kappa B (NFκB) and activator protein-1 (AP-1)
transcriptional activity were assessed by reporter gene assay. The effects of EGCG on glucose oxidase (GO)-induced
reactive oxygen species (ROS) production was determined using the ROS probe CM-H2DCFDA.
Results: Treatment of HCEpiC with 1 ng/ml IL-1β for 18 h significantly increased release of the cytokines/chemokines
granulocyte  colony-stimulating  factor  (G-CSF),  granulocyte-macrophage  colony-stimulating  factor  (GM-CSF),
interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1), while hyperosmolarity-induced
release of IL-6 and MCP-1. When cells were treated with IL-1β and EGCG or hyperosmolarity and EGCG there was a
dose-dependent reduction in release of these cytokines/chemokines, with significant inhibition observed at 3–30 µM.
There was no effect of EGCG on cell metabolic activity at any of the doses tested (0.3–30 µM). EGCG significantly
inhibited phosphorylation of the MAPKs p38 and c-Jun N-terminal kinase (JNK), and NFκB and AP-1 transcriptional
activities. There was a significant dose-dependent decrease in GO-induced ROS levels after treatment of HCEpiC with
EGCG.
Conclusions: EGCG acts as an anti-inflammatory and anti-oxidant agent in HCEpiC and therefore may have therapeutic
potential for ocular inflammatory conditions such as dry eye.
The corneal epithelium acts both as an initial physical
barrier to insult and infection, and also as a key player in the
ocular  immune  response  by  producing  inflammatory
cytokines [1]. Ocular surface inflammation can be induced by
numerous insults including the presence of pathogens, allergic
reaction, and dry eye disease. While acute inflammation is
essential  for  healing,  chronic  inflammation  contributes  to
epithelial damage and cell death [2].
Dry eye disease is associated with inflammation of the
ocular  surface,  and  hyperosmolarity  of  the  tears  is  now
recognized as an important mediator of this inflammatory
response [3,4]. Increased tear osmolarity causes a signaling
cascade  which  involves  phosphorylation  of  the  stress-
activated mitogen activated protein kinases (MAPKs) p38 and
c-Jun N-terminal kinase (JNK) [5-9], followed by activation
of transcription factors such as activator protein-1 (AP-1) and
nuclear factor kappa B (NFκB), resulting in increased levels
of  pro-inflammatory  cytokines  such  as  IL-1β,  TNF-α,
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interleukin-8  (IL-8),  and  interleukin-6  (IL-6)  [8-14].
Increased levels of IL-1β at the ocular surface contributes to
the epithelial damage observed in dry eye and also infectious
eye diseases with an inflammatory component by inducing
expression of other pro-inflammatory cytokines in corneal
epithelial cells and other ocular cells [15-17].
Another contributor to the cellular damage which occurs
during inflammation is oxidative stress [18,19]. It has been
demonstrated  that  lipid  peroxide  and  myeloperoxidase
activity are increased in the tears of dry eye patients, indicating
increased  oxidative  potential  [20].  In  addition,  increased
oxidative stress markers and reactive oxygen species (ROS)
production in the corneal epithelia of blink-suppressed dry
eyes has been reported [21]. The ability of antioxidants to
reduce the inflammatory reaction in acute inflammation and
experimental  infectious  keratitis  indicates  that  reactive
oxygen species play a role in corneal inflammatory diseases
[22,23].
Epigallocatechin gallate (EGCG) is the major polyphenol
found in green tea, which is produced from the Carmellia
sinensis plant. EGCG has been demonstrated to have both
anti-inflammatory and anti-oxidant properties in multiple cell
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533types [24-29]. Because of these properties, it is thought that
EGCG  may  have  therapeutic  benefit  in  numerous
inflammatory diseases such as atherosclerosis, arthritis, and
dry eye disease [30-32]. Therefore, the objective of the current
study  was  to  determine  the  effects  of  EGCG  on  pro-
inflammatory  and  pro-oxidant  stimuli  in  human  corneal
epithelial cells (HCEpiC). Our data demonstrate that EGCG
exhibits both anti-inflammatory and anti-oxidant properties in
HCEpiC. To investigate the mechanistic basis for the anti-
inflammatory effects of EGCG in HCEpiC, we determined its
effect  on  the  activation  of  MAPKs  p38  and  JNK  and
transcription factors NFκB and AP-1.
METHODS
Reagents:  EpiLife  medium,  human  corneal  growth
supplement  (HCGS),  penicillin-streptomycin  solution,
alamarBlue  solution,  Lipofectamine  LTX,  and  Opti-MEM
were obtained from Invitrogen (Carlsbad, CA). EGCG was
from DSM (Basel, Switzerland) and IL-1β was from R&D
Systems (Minneapolis, MN). Human multiplex-cytokine kits
were from Millipore (Billerica, MA). Fast Activated Cell-
based ELISA (FACE) p38 and JNK ELISA kits were from
Active Motif (Carlsbad, CA). Cignal AP1 reporter (luc) and
Cignal NFκB reporter (luc) kits were purchased from SA
Biosciences  (Frederick,  MD).  Dual-Glo  Luciferase  assay
system was from Promega (Madison, WI). All other reagents
were purchased from standard commercial sources and were
of the highest available purity.
Cells  and  treatments:  SV40-transformed  human  corneal
epithelial cells (HCEpiC) were received at passage 20 from
ATCC (Manassas, VA), and maintained in EpiLife medium
supplemented  with  HCGS,  100  U/ml  of  penicillin,  and
100 µg/ml of streptomycin at 37 °C in a humidified incubator
with  5%  CO2.  Cells  were  cultured  in  glucocorticoid-free
medium (EpiLife basal medium supplemented with 12.5 μg/
ml bovine pituitary extract, 1.25 μg/ml bovine insulin, and
1.25  ng/ml  EGF)  for  48  h  before  exposure  to  IL-1β  or
hyperosmolar  medium.  Osmolarity  was  increased  to  440
mOsM by the addition of 123 mM sucrose to basal EpiLife
medium (at 317 mOsM). Osmolarity of the solutions was
verified using an osmometer (Osmette; Advanced Intruments,
Norwood,  MA).  EGCG  stock  solutions  were  prepared  in
DMSO. Each treatment was performed in at least triplicate,
and appropriate dilutions were prepared to deliver a constant
amount of the vehicle to each well. Lack of an effect of
treatments on cell metabolic activity, an index of cell viability,
was determined by the alamarBlue assay [33,34].
Cytokine release by multiplex Luminex: HCEpiC were seeded
on 48-well plates at a density of 2×104 cells per well. After 72
h, cells were treated with vehicle (0.1% DMSO) or EGCG for
18 h with 1 ng/ml IL-1β or 24 h in 440 mOsM hyperosmolar
basal media. Cytokine content in the culture medium was
analyzed using multiplex Luminex bead technology [35,36]
according to the manufacturer's instructions. Briefly, 25 μl of
medium  samples  were  incubated  with  antibody-coated
capture beads overnight at 4 °C. Washed beads were further
incubated with biotin-labeled anti-human cytokine antibodies
for 1 h at room temperature followed by incubation with
streptavidin-phycoerythrin  for  30  min.  Samples  were
analyzed using Luminex 200™ (Luminex, Austin, TX) and
Statlia software (Brendan Technologies Inc., Carlsbad, CA).
Standard  curves  of  known  concentrations  of  recombinant
human cytokines were used to convert median fluorescence
intensity (MFI) to cytokine concentration in pg/ml. Only the
linear portions of the standard curves were used to quantify
cytokine concentrations.
Cell-based  ELISA  for  determination  of  p38  and  JNK
phosphorylation: Cells were seeded on a 96-well plate at a
density of 1×104 cells per well. After 48 h, the medium was
replaced  with  basal  medium  for  18  h.  Due  to  the  short
incubation  time  necessary  for  measurement  of  MAPK
phosphorylation, cells were pre-treated with EGCG for 2 h in
basal medium. Cells were then treated with 1 ng/ml IL-1β
alone or with EGCG at 3 or 30 μM, or hyperosmolar media
alone or with EGCG at 3 or 30 μM for 30 min. Levels of
phosphorylated and total p38 or JNK were measured using a
cell-based  ELISA  according  to  the  manufacturer’s
instructions.  Briefly,  the  cells  were  fixed  with  4%
formaldehyde in PBS. After blocking, cells were incubated
with  primary  antibodies  specific  to  the  appropriate
phosphorylated or total MAPK overnight at 4 °C. Negative
controls were performed using secondary antibody only. After
washing,  cells  were  incubated  with  HRP-conjugated
secondary  antibody  for  1  h  followed  by  further  washing.
Chemiluminescent reagent was added to each well and the
resulting luminescence was read on a Synergy plate reader
(Biotek,  Winooski,  VT).  To  verify  that  cell  number  was
unchanged  by  treatments,  cells  in  each  well  were  further
stained with crystal violet. The absorbance was read on a
Synergy plate reader at 595 nm. Data were expressed as the
ratio of phosphorylated to total MAPK, and were normalized
by cell number.
Western  blotting  for  determination  of  p38  and  JNK
phosphorylation: HCEpiC were preincubated with EGCG or
vehicle control in EpiLife medium without growth factors for
2 h, and then were stimulated for 30 min with 1 ng/ml IL-1β.
The cells were washed with ice-cold PBS and lysed in cell
lysis  buffer  (62.5  mM  Tris-HCl,  pH  6.8,  2%  SDS,  10%
glycerol and 1:1,000 protein inhibitor cocktail [PIC; Sigma,
St Louis, MO]). Cells were sonicated, centrifuged at 12,800×
g, and protein amount was determined using a Micro BCA
protein assay kit (Pierce, Rockford, IL). Aliquots of cell lysate
(30  μg)  were  separated  by  SDS-polyacrylamide
electrophoresis and transferred to nitrocellulose membranes
for western analysis. Membranes were blocked with 5% BSA
and exposed to phospho p38 or phospho JNK antibody (Cell
Signaling,  Danvers,  MA).  The  blots  were  washed,  and
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534exposed to horseradish peroxidase (HRP) secondary antibody
(Bio-Rad, Hercules, CA). After washing, blots were incubated
in  enhanced  chemiluminescence  signal  (Pierce)  and
visualized using the Alpha Innotech Imaging system (Cell
Biosciences, Santa Clara, CA). Blots were then stripped with
Restore stripping solution (Pierce) and incubated in total p38
or JNK antibody, followed by HRP secondary antibody as a
loading control.
AP-1  and  NFκB  transcriptional  activity:  The  AP-1  and
NFκB  transcriptional  activities  were  measured  using  an
inducible reporter construct which encoded a firefly luciferase
reporter gene under the control of a basal promoter element
(TATA box) joined to tandem repeats of specific AP-1 or
NFκB  transcriptional  response  elements.  This  vector  was
mixed  with  a  constitutively  expressing  Renilla  construct
(which was used as a normalizer) at a ratio of 40:1. pRSVT-
HCEpiC  were  seeded  on  a  96-well  plate  at  a  density  of
1×104 cells per well. After 24 h 200 ng of AP-1 or NFκB
construct  was  transfected  using  Lipofectamine  LTX
transfection reagent (Invitrogen). Thirty h after transfection,
cells were treated with vehicle (0.1% DMSO), IL-1β or 440
mOsm media, and 3 or 30 μM EGCG for 16 h in basal medium.
Firefly and Renilla luciferase activity was measured using the
Dual-Glo  luciferase  assay  system  (Promega).  Background
relative luminescence units (RLU) were subtracted and the
ratio of firefly luciferase/Renilla luciferase luminescence was
then calculated.
Reactive  oxygen  species  levels:  The  effect  of  EGCG  on
glucose  oxidase-induced  reactive  oxygen  species  (ROS)
generation was determined using the dye chloromethyl-2’,7’-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA). CM-
H2DCFDA passively diffuses into cells, where it covalently
binds to intracellular components, trapping the dye within the
cell.  Non-fluorescent  CM-H2DCFDA  becomes  highly
fluorescent when oxidized by ROS. Cells were pretreated with
EGCG in basal EpiLife media for 1 h before dye loading. Cells
were then loaded with 10 μM CM-H2DCFDA in basal EpiLife
media for 30 min and washed with PBS. Cells were then
exposed to vehicle, 50 mU glucose oxidase (GO), or GO +
EGCG in EpiLife basal media for 1 h after which fluorescence
was measured on a Synergy plate reader (BioTek, Winooski,
VT). A control experiment in which EGCG was incubated
with CM-DCF dye verified there was no effect of EGCG on
the fluorescence emitted by the dye.
Statistical  analysis:  Data  were  expressed  as  mean±SEM.
Statistical analysis was performed using a one-way ANOVA-
Dunnett’s  test  with  the  statistical  software  JMP8  (SAS
Institute,  Cary,  NC).  P  values  less  than  0.05  were  pre-
determined to be statistically significant. Experiments were
performed at least in triplicate.
RESULTS
EGCG inhibits IL-1β- and hyperosmolar-induced cytokine
release: Treatment of HCEpiC with 1 ng/ml IL-1β for 18 h
significantly increased release of the cytokines/chemokines
G-CSF, GM-CSF, IL-6, IL-8, and MCP-1. When cells were
Figure 1. EGCG inhibits IL-1β-induced
cytokine release in HCEpiC. Cells were
cultured  in  complete  (HCGS-
containing)  medium,  followed  by
glucocorticoid-free  medium  for  18  h.
Cells  were  then  treated  with  1  ng/ml
IL-1β in the presence of EGCG for 18 h.
G-CSF  (A),  GM-CSF  (B),  IL-6  (C),
IL-8 (D), and MCP-1 (E) levels in the
media  were  analyzed  by  Luminex.
White bar represents control; black bar
represents  IL-1β;  gray  bar  represents
EGCG  alone,  black  circles  +  line
represent EGCG. Lines are the linear
interpolation between data points. Data
are  presented  as  mean±SEM,  n=3.
*versus IL-1β; p<0.05.
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535treated with IL-1β and EGCG there was a dose-dependent
decrease  in  release  of  these  cytokines/chemokines,  with
significant inhibition observed at 3 – 30 μM (Figure 1).
Increased tear osmolarity is a key factor in dry eye disease
[3,4], therefore the effect of EGCG on hyperosmolar-induced
cytokine  release  was  determined.  There  was  a  significant
increase  in  IL-6  and  MCP-1  release  when  the  medium
osmolarity was increased from 317 mOsm to 440 mOsm for
24 h. There was a dose-dependent inhibition of hyperosmolar-
induced IL-6 and MCP-1 release, with significant inhibition
observed at 10 and 30 μM for IL-6 and 30 μM for MCP-1
(Figure 2A,B).
To verify that the inhibitory effect of EGCG on cytokine
release was not due to cellular toxicity an alamarBlue assay
was performed. There was a small, yet significant increase in
metabolic activity in cells treated with IL-1β as compared to
control (Figure 3A). However, there was no effect of IL-1β +
EGCG or hyperosmolarity + EGCG on cell metabolic activity
at any of the doses tested (0.3–30 μM; Figure 3A,B). These
data  demonstrate  that  EGCG  can  inhibit  inflammatory
cytokines induced by multiple stimuli in HCEpiC.
EGCG  reduces  IL-1β-  and  hyperosmolar-induced
phosphorylation/activation  of  p38  and  JNK  MAPK:  To
investigate  the  possible  mechanisms  underlying  the  anti-
inflammatory effects of EGCG, its effects on phosphorylation
of the MAPKs p38 and JNK were determined. Quantitative
cell-based  ELISA  and  semi-quantitative  western  blotting
were  performed  using  phospho-specific  antibodies  against
JNKs at Thr183/Tyr185, and against p38 at Thr180/Tyr182.
These sites have been demonstrated to be associated with the
activation state of these proteins [37]. Exposure of HCEpiC
to  1  ng/ml  IL-1β  induced  an  increase  in  the  ratio  of
Figure 2. EGCG inhibits hyperosmolar-
induced  cytokine  release  in  HCEpiC.
Cells  were  cultured  in  complete
(HCGS-containing) medium, followed
by glucocorticoid-free medium for 18 h.
Cells were then treated with 440 mOsm
hyperosmotic  basal  media  in  the
presence of EGCG for 24 h. IL-6 (A) and
MCP-1 (B) release into the media was
analyzed  by  Luminex.  White  bar
represents control (317 mOsm); black
bar  represents  hyperosmolarity  (440
mOsm);  gray  bar  represents  EGCG
alone;  black  circles  +  line  represents
EGCG. Lines are the linear interpolation
between data points. Data are presented
as mean±SEM, n=3. *versus 440 mOsm
hyperosmotic media; p<0.05.
Figure  3.  Effects  of  EGCG  on  cell
metabolic  activity  in  HCEpiC.  Cells
were  cultured  in  complete  (HCGS-
containing)  medium,  followed  by
glucocorticoid-free  medium  for  18  h.
Cells were then treated with IL-1β (A)
or 440 mOsm hyperosmotic basal media
(B) in the presence of EGCG for 18 or
24  h,  respectively.  Cell  metabolic
activity  was  determined  using  an
alamarBlue assay. Data are presented as
mean±SEM,  n=3.  *versus  IL-1β  for
panel A and 440 mOsm media for panel
B; p<0.05.
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536phosphorylated to total p38 and JNK, indicating an increase
in activity of these inflammatory signaling mediators (Figure
4).  Figure  4A,B  shows  that  both  p38  and  JNK
phosphorylation,  as  measured  by  cell-based  ELISA  and
normalized to total p38 or JNK, were significantly inhibited
by 3, 10, or 30 μM EGCG. Similar results were obtained using
western  blotting  techniques.  Both  3  and  30  μM  EGCG
significantly inhibited phosphorylation of IL-1β-induced p38
and  p46  JNK  with  no  change  in  total  p38  or  p46  JNK
expression, however p54 JNK phosphorylation was unaltered
by 1 ng/ml IL-1β or EGCG (Figure 4C,D).
The effect of EGCG on hyperosmolar-induced p38 and
JNK  phosphorylation  was  also  determined  by  cell-based
ELISA.  There  was  a  significant  increase  in  p38
phosphorylation when cells were exposed to hyperosmolarity
for 30 min, however the JNK phosphorylation increase did not
reach significance. Hyperosmolar-induced phosphorylation
of p38 was significantly decreased when cells were treated
with 3 and 30 µM EGCG, as compared to hyperosmolarity
alone (Figure 5A). There was also a significant inhibition of
JNK phosphorylation at 30 μM EGCG (Figure 5B).
EGCG suppresses IL-1β- and hyperosmolar-induced AP-1
and NFκB transcriptional activation: It has been reported that
MAPK  phosphorylation  leads  to  activation  of  the
transcription factors AP-1 and NFκB, and that furthermore,
EGCG treatment leads to AP-1 and NFκB suppression in
many cell types [30,31,38]. Therefore, the effect of EGCG on
activation of AP-1 and NFκB was determined in HCEpiC.
Luciferase reporter gene constructs containing tandem repeats
of NFκB or AP-1 specific transcriptional response elements
were  transiently  transfected  into  HCEpiC  together  with  a
constitutively expressing Renilla construct as a normalizer.
Cells were then treated with 1 ng/ml IL-1β (Figure 6A,B) or
440 mOsm hyperosmolarity (Figure 6C,D) in combination
with  EGCG.  Figure  6A,B  shows  that  NFκB  and  AP-1
transcriptional  activities  were  significantly  increased  by
Figure 4. Effects of EGCG on IL-1β-
induced phosphorylated p38 and JNK
levels in HCEpiC. Cells were cultured
in  complete  (HCGS-containing)
medium, followed by basal medium for
18 h. Cells were pre-treated with EGCG
for  2  h.  Cells  were  then  treated  with
IL-1β  +  EGCG  for  30  min.
Phosphorylated  p38  and  JNK  levels
were determined by cell-based ELISA
(upper  panels)  or  western  blotting
(lower panels). A: effect of EGCG on
IL-1β-induced  phosphorylated  p38
determined  by  cell-based  ELISA;  B:
effect  of  EGCG  on  IL-1β-induced
phosphorylated  JNK  determined  by
cell-based ELISA; C: effect of EGCG
on IL-1β-induced phosphorylated p38
determined by western blotting, Upper
panel: upper blot shows phosphorylated
p38. Lower blot is after stripping and
probing with total p38 antibody. Lower
panel:  densitometric  analysis  of
phosphorylated p38 normalized by total
p38.  D.  effect  of  EGCG  on  IL-1β-
induced  phosphorylated  JNK
determined by western blotting, Upper
panel: upper blot shows phosphorylated
JNK. Lower blot is after stripping and
probing with total JNK antibody. Lower
left  panel:  densitometric  analysis  of
phosphorylated p46 JNK normalized by
total  p46  JNK;  lower  right  panel:
densitometric  analysis  of
phosphorylated p54 JNK normalized by
total p54 JNK. For A and B, n=6, For
C and D, n=3–4. Representative blots
are shown. *versus IL-1β; p<0.05.
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537IL-1β.  EGCG  at  3  or  30  μM  reduced  this  IL-1β-induced
transcriptional  activity  to  control  levels.  Similarly,
hyperosmolarity  induced  both  AP-1  and  NFκB  activities
(Figure  6C,D).  Hyperosmolar-induced  AP-1  activity  was
significantly decreased by 3 and 30 μM EGCG, while there
was no inhibition of NFκB activity.
EGCG inhibits glucose oxidase-induced ROS in HCEpiC:
EGCG is a well known anti-oxidant in many cell types, and
since oxidative stress is a key component of the inflammatory
cascade,  the  effect  of  EGCG  on  ROS  in  HCEpiC  was
determined. The ROS generator glucose oxidase significantly
increased ROS levels in HCEpiC after 1 h, as determined
using  CM-H2DCF-DA  dye.  There  was  a  dose-dependent
inhibition of glucose oxidase-induced ROS, with significant
inhibition observed at 3, 10, and 30 μM EGCG (Figure 7),
demonstrating that EGCG acts as an anti-oxidant in HCEpiC.
DISCUSSION
In this study we determined that the green tea polyphenol
EGCG has both anti-inflammatory and anti-oxidant properties
in HCEpiC. Two pro-inflammatory stimuli were selected to
challenge  the  HCEpiC,  IL-1β,  and  hyperosmolarity.  The
importance of IL-1β in the etiology of corneal inflammatory
disease such as dry eye and keratitis has been demonstrated
in multiple cell types [15-17,39-41]. An increase in osmolarity
of the tear film is known to be one of the causative factors in
dry eye, resulting in inflammation and subsequent cell damage
[3,4]. In addition, studies have demonstrated that increased
osmolarity  elevates  levels  of  cytokines  and  matrix
metalloproteases in corneal epithelial cells [5-7], in in vivo
dry eye models [8,9] and in the tears of dry eye patients
[11-14]. EGCG was effective in inhibiting multiple cytokines
induced by both these inflammatory mediators, demonstrating
it may have therapeutic potential in the treatment of corneal
inflammatory diseases, including dry eye. These data are in
agreement with an in vivo study which demonstrated that
topical EGCG was efficacious for the treatment of dry eye
disease  [32].  Furthermore,  we  demonstrate  that  EGCG
exhibited potent anti-oxidant activity in HCEpiC, inhibiting
reactive oxygen species generated by the pro-oxidant glucose
oxidase.
EGCG is reported to possess both anti-inflammatory and
anti-oxidant properties in vitro and in vivo [24-27,30-32]. In
the eye, green tea extract protects the lens and retina from UV-
induced oxidation [28,29,42] and reduces retinal oxidative
glutamate toxicity [43]. While the anti-inflammatory and anti-
oxidant properties of EGCG are well described in multiple
ocular and non-ocular cell types, to our knowledge, this is the
first  study  demonstrating  these  properties  and  their
mechanistic  basis  in  corneal  epithelial  cells.  The  stress-
activated MAPKs p38 and JNK are known to play a key role
in regulating the production of pro-inflammatory cytokines
Figure  5.  Effects  of  EGCG  on
hyperosmolar-induced  phosphorylated
p38 and JNK levels in HCEpiC. Cells
were  cultured  in  complete  (HCGS-
containing) medium, followed by basal
medium for 18 h. Cells were pre-treated
with  EGCG  for  2  h.  Cells  were  then
treated with 440 mOsm hyperosmotic
media  +  EGCG  for  30  min.
Phosphorylated  p38  and  JNK  levels
were determined by cell-based ELISA.
A: effect of EGCG on hyperosmolar-
induced phosphorylated p38; B: effect
of  EGCG  on  hyperosmolar-induced
phosphorylated JNK; n=6, *versus 440
mOsm media; p<0.05.
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538leading to inflammation. EGCG has been shown to inhibit
both JNK and p38 in multiple cell types [31,44]. We found
that EGCG inhibited the IL-1β- and hyperosmolar-induced
phosphorylation/activation of both p38 and JNK in HCEpiC.
EGCG  was  comparably  potent  at  inhibiting  both  IL-1β-
induced p38 and JNK activation, with significant inhibition at
3  μM.  However,  EGCG  appeared  more  efficacious  at
inhibiting hyperosmolar-induced p38 phosphorylation than
JNK, with significant inhibition at 3 μM for p38 as compared
to 30 μM for JNK.
Figure 6. Effects of EGCG on IL-1β-
and hyperosmolarity-induced HCEpiC
NFκB  and  AP-1  activity.  Cells  were
transfected  with  an  AP-1  or  NFκB
reporter gene (expressing firefly) and a
constitutively  expressing  Renilla
construct  and  then  placed  in
glucocorticoid-free  medium  for  24  h.
Thirty h after transfection, cells were
treated with IL-β (panels A and B) or
440 mOsM media (panels C and D) in
the presence or absence of EGCG. Cells
were  assayed  for  firefly  luciferase
followed  by  Renilla  luciferase
luminescence  48  h  after  transfection.
Data  are  expressed  as  normalized
firefly:  Renilla  luciferase  ratio.  A:
Effect of EGCG on IL-1β-induced AP-1
transcriptional  activity;  B:  effect  of
EGCG  on  IL-1β-induced  NFκB
transcriptional  activity.  C:  Effect  of
EGCG  on  440  mOsm  hyperosmolar-
induced  AP-1  transcriptional  activity;
B:  effect  of  EGCG  on  440  mOsm
hyperosmolar-induced  NFκB
transcriptional activity. Data are mean
±SEM,  n=6.  For  A  and  B,  *versus
IL-1β; for C and D, *versus 440 mOsm
media; p<0.05.
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539Two transcription factors known to mediate the increases
in cytokine production by both IL-1β and hyperosmolarity are
AP-1  and  NFκB  [45,46].  AP-1  is  regulated  by  multiple
MAPKs – ERKs activate AP-1 after mitogenic stimulation of
cells, in contrast JNK and p38 activate AP-1 after exposure of
cells to environmental stress or proinflammatory cytokines
[47]. NFκB is commonly made up of a heterodimer between
the p65 subunit (also known as Rel A), which contains a
transactivation  domain  mediating  transcriptional  induction
and the p50 subunit. NFκB is predominantly activated through
phosphorylation by inhibitory protein kappa B (IκB) kinase
and subsequent degradation of the bound IκB, allowing it to
translocate  to  the  nucleus  [2].  Our  results  indicate  that
inhibition of IL-1β-induced cytokine expression by EGCG is
mediated, at least in part, by inhibition of both AP-1 and
NFκB transcriptional activities. Inhibition of AP-1 activity by
EGCG is presumably due to its effect on MAPK signaling and
EGCG may also affect DNA binding activity of AP-1 as has
been demonstrated in other cell types [31,48]. The effects of
EGCG  on  NFκB  in  other  cell  types  are  through  multiple
Figure 7. Effect of EGCG on glucose oxidase-induced ROS levels
in HCEpiC. Cells were cultured in complete (HCGS-containing)
medium, followed by glucocorticoid-free medium for 18 h. Cells
were pretreated with EGCG for 1 h, loaded with CM-H2DCFDA for
30 min, followed by treatment with 50 mU/ml glucose oxidase and
EGCG for 1 h. White bar represents control; black bar represents
glucose oxidase (GO) alone; black circles indicate glucose oxidase
and EGCG. n=4, *versus GO, p<0.05.
mechanisms,  including  inhibition  of  IκB  kinase,  IκB
phosphorylation,  p65NFκB  phosphorylation,  p65NFκB
acetylation, and NFκB DNA binding activity [31,48,49].
While hyperosmolar-induced AP-1 activity was inhibited
by  hyperosmolarity,  NFκB  activity  was  not  affected  by
EGCG. Incomplete inhibition of AP-1 activity and lack of
effect  on  NFκB  activity  by  EGCG  suggests  that  EGCG
inhibits hyperosmolar-induced cytokine levels at additional
steps in the hyperosmolarity-induced signaling cascade. For
example, the transcription factor nuclear factor of activated
T-cell-5 (NFAT5) is induced and activated in limbal epithelial
cells by hyperosmolarity [50]. Signal transducer and activator
of  transcription  (STAT1)  is  another  factor  known  to  be
activated by hyperosmolarity in several cell types [51,52], is
expressed in human corneal epithelial cells [53], and is also a
target of EGCG [54-56]. Another possibility is that EGCG
could down-regulate cytokine gene expression at the post-
transcriptional level through effects on mRNA stability [57].
Elucidating  the  additional  mechanisms  by  which  EGCG
affects hyperomolar-induced cytokine release is an interesting
area for future research.
In summary, these data demonstrate EGCG acts as an
anti-inflammatory  and  anti-oxidant  agent  in  HCEpiC
challenged with either the pro-inflammatory cytokine IL-1β
or  hyperosmolarity.  Therefore,  EGCG  has  potential
therapeutic application for the treatment of ocular disorders
with an inflammatory component, including dry eye.
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